TerminatedPhase 4

Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer)

Stopped: Logistical challenges; no safety concerns

United States5 participantsStarted 2018-10-05

Plain-language summary

The main reason for this study is to see if Acthar Gel can reduce inflammation in the uvea. Also, safety information when using it for this purpose will be collected.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Has active, inflammatory, chorioretinal and/or inflammatory retinal vascular lesion
✓. Has ≥ 2+ anterior chamber cells \[Standardization of Uveitis Nomenclature (SUN) criteria\]
✓. Has ≥ 1.5+ vitreous haze

What they're measuring

Score on the Nussenblatt Grading Scale

Timeframe: Week 36

Score on the Laser Flare Scale

Timeframe: Week 36

Score on the Aqueous Cell Scale

Timeframe: Week 36

Trial details

NCT IDNCT03656692

SponsorMallinckrodt

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2020-07-14

Results submitted2021-06-18

View on ClinicalTrials.gov More Uveitis, Posterior trials